Skip to main content

Table 4 Logistic regression model: abandonment of initial oncolytic prescription

From: Impact of pharmacy channel on adherence to oral oncolytics

Determinant Odds Ratio 95% CI
Age, Reference <65 years
  ≥ 65 years 1.25 1.04–1.51
Gender, Reference Female
 Male 1.16 0.99–1.36
Geographic Region, Reference South
 Northeast 0.64 0.51–0.81
 Midwest 1.10 0.90–1.35
 West 1.00 0.78–1.27
 Other/missing 1.48 1.01–2.17
Population, Reference Retail Pharmacy
 Specialty 0.44 0.35–0.55
Copay, Reference $0–49
 $50–100 1.55 1.14–2.12
 $101–150 1.55 1.02–2.35
 $151–200 1.94 1.17–3.24
 $201–250 3.43 2.15–5.47
 $251–350 4.54 3.00–6.93
 $351–500 5.22 3.65–7.46
 $501–1000 4.89 3.71–6.44
  > $1000 13.69 10.87–17.23
Index Oncolytic, Reference Erlotinib
 Capecitabine 1.41 1.15-1.74
 Imatinib 0.94 0.73-1.22
  1. Abbreviations: CI confidence interval